Drug profile · INN
denosumab-bbdz
JUBBONTI
denosumab-bbdz (JUBBONTI) is a tumor necrosis factor ligand superfamily member 11 inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — denosumab-bbdz
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
denosumab-bbdz (JUBBONTI) is a tumor necrosis factor ligand superfamily member 11 inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Tumor necrosis factor ligand superfamily member 11 inhibitor
Primary target: Tumor necrosis factor ligand superfamily member 11
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is denosumab-bbdz?
denosumab-bbdz (JUBBONTI) is a tumor necrosis factor ligand superfamily member 11 inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for denosumab-bbdz?
JUBBONTI is a marketed brand name for denosumab-bbdz. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of denosumab-bbdz?
denosumab-bbdz has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.